These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 34844930)

  • 1. Immunogenicity of the COVID-19 mRNA vaccine in adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors.
    Dimopoulou D; Vartzelis G; Dasoula F; Tsolia M; Maritsi D
    Ann Rheum Dis; 2022 Apr; 81(4):592-593. PubMed ID: 34844930
    [No Abstract]   [Full Text] [Related]  

  • 2. Methotrexate and glucocorticoids, but not anticytokine therapy, impair the immunogenicity of a single dose of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic inflammatory arthritis.
    Bugatti S; De Stefano L; Balduzzi S; Greco MI; Luvaro T; Cassaniti I; Bogliolo L; Mazzucchelli I; D'Onofrio B; di Lernia M; Mauric E; Lilleri D; Baldanti F; Manzo A; Montecucco C
    Ann Rheum Dis; 2021 Dec; 80(12):1635-1638. PubMed ID: 34172502
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunogenicity and Safety of COVID-19 mRNA Vaccine in STAT1 GOF Patients.
    Bloomfield M; Parackova Z; Hanzlikova J; Lastovicka J; Sediva A
    J Clin Immunol; 2022 Feb; 42(2):266-269. PubMed ID: 34718945
    [No Abstract]   [Full Text] [Related]  

  • 4. Poor Humoral Response in Solid Organ Transplant Recipients Following Complete mRNA SARS-CoV-2 Vaccination.
    Cao J; Liu X; Muthukumar A; Gagan J; Jones P; Zu Y
    Clin Chem; 2021 Dec; 68(1):251-253. PubMed ID: 34358295
    [No Abstract]   [Full Text] [Related]  

  • 5. Immunogenicity 6 months post COVID-19 mRNA vaccination among adolescents with juvenile idiopathic arthritis on treatment with TNF inhibitors.
    Dimopoulou D; Tsolia MN; Spyridis N; Maritsi DN
    Rheumatology (Oxford); 2023 Feb; 62(SI2):SI205-SI209. PubMed ID: 35788275
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and tolerability of the COVID-19 messenger RNA vaccine in adolescents with juvenile idiopathic arthritis treated with tumor necrosis factor inhibitors.
    Dimopoulou D; Spyridis N; Vartzelis G; Tsolia MN; Maritsi DN
    Arthritis Rheumatol; 2022 Feb; 74(2):365-366. PubMed ID: 34492161
    [No Abstract]   [Full Text] [Related]  

  • 7. Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer.
    Ehmsen S; Asmussen A; Jeppesen SS; Nilsson AC; Østerlev S; Vestergaard H; Justesen US; Johansen IS; Frederiksen H; Ditzel HJ
    Cancer Cell; 2021 Aug; 39(8):1034-1036. PubMed ID: 34348121
    [No Abstract]   [Full Text] [Related]  

  • 8. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases.
    Spiera R; Jinich S; Jannat-Khah D
    Ann Rheum Dis; 2021 Oct; 80(10):1357-1359. PubMed ID: 33975857
    [No Abstract]   [Full Text] [Related]  

  • 10. Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis.
    Simader E; Tobudic S; Mandl P; Haslacher H; Perkmann T; Nothnagl T; Sautner J; Radner H; Winkler F; Burgmann H; Mrak D; Aletaha D; Winkler S; Blüml S
    Ann Rheum Dis; 2022 Mar; 81(3):416-421. PubMed ID: 34844927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with juvenile idiopathic arthritis on TNF inhibitors exposed to COVID-19 family members.
    Marino A; Romano M; Gattinara M; Cimaz R
    Semin Arthritis Rheum; 2020 Dec; 50(6):1214-1215. PubMed ID: 33059294
    [No Abstract]   [Full Text] [Related]  

  • 12. Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants.
    Qu P; Faraone JN; Evans JP; Zheng YM; Yu L; Ma Q; Carlin C; Lozanski G; Saif LJ; Oltz EM; Gumina RJ; Liu SL
    N Engl J Med; 2022 Oct; 387(14):1329-1331. PubMed ID: 36069925
    [No Abstract]   [Full Text] [Related]  

  • 13. SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response.
    Bonelli MM; Mrak D; Perkmann T; Haslacher H; Aletaha D
    Ann Rheum Dis; 2021 Oct; 80(10):1355-1356. PubMed ID: 33958323
    [No Abstract]   [Full Text] [Related]  

  • 14. Correspondence on 'SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response'.
    Westhoff TH; Seibert FS; Anft M; Blazquez-Navarro A; Skrzypczyk S; Doevelaar A; Hölzer B; Paniskaki K; Dolff S; Wilde B; Witzke O; Braun J; Stervbo U; Babel N
    Ann Rheum Dis; 2021 Oct; 80(10):e162. PubMed ID: 34272253
    [No Abstract]   [Full Text] [Related]  

  • 15. Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022.
    Halasa NB; Olson SM; Staat MA; Newhams MM; Price AM; Boom JA; Sahni LC; Cameron MA; Pannaraj PS; Bline KE; Bhumbra SS; Bradford TT; Chiotos K; Coates BM; Cullimore ML; Cvijanovich NZ; Flori HR; Gertz SJ; Heidemann SM; Hobbs CV; Hume JR; Irby K; Kamidani S; Kong M; Levy ER; Mack EH; Maddux AB; Michelson KN; Nofziger RA; Schuster JE; Schwartz SP; Smallcomb L; Tarquinio KM; Walker TC; Zinter MS; Gilboa SM; Polen KN; Campbell AP; Randolph AG; Patel MM; ;
    MMWR Morb Mortal Wkly Rep; 2022 Feb; 71(7):264-270. PubMed ID: 35176002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SARS-CoV-2 Vaccines: Much Accomplished, Much to Learn.
    Connors M; Graham BS; Lane HC; Fauci AS
    Ann Intern Med; 2021 May; 174(5):687-690. PubMed ID: 33460347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort.
    Geisen UM; Berner DK; Tran F; Sümbül M; Vullriede L; Ciripoi M; Reid HM; Schaffarzyk A; Longardt AC; Franzenburg J; Hoff P; Schirmer JH; Zeuner R; Friedrichs A; Steinbach A; Knies C; Markewitz RD; Morrison PJ; Gerdes S; Schreiber S; Hoyer BF
    Ann Rheum Dis; 2021 Oct; 80(10):1306-1311. PubMed ID: 33762264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA Vaccination in Immunocompromised Patients.
    Schulz E; Hodl I; Forstner P; Hatzl S; Sareban N; Moritz M; Fessler J; Dreo B; Uhl B; Url C; Grisold AJ; Khalil M; Kleinhappl B; Enzinger C; Stradner MH; Greinix HT; Schlenke P; Steinmetz I
    Front Immunol; 2021; 12():803742. PubMed ID: 34950155
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful BNT162b2 booster vaccinations in a patient with rheumatoid arthritis and initially negative antibody response.
    Albach FN; Burmester GR; Biesen R
    Ann Rheum Dis; 2021 Oct; 80(10):1361-1362. PubMed ID: 34167947
    [No Abstract]   [Full Text] [Related]  

  • 20. Persistent Immunogenicity of the mRNA COVID-19 Vaccine in Patients Vaccinated Before Kidney Transplant.
    Yi SG; Eagar T; Moore L; Huang HJ; Ibrahim H; Hobeika MJ; McMillan R; Podder H; Ghobrial RM; Gaber AO; Knight RJ
    Transplantation; 2021 Oct; 105(10):e133-e134. PubMed ID: 34155187
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.